Rhythm expands obesity portfolio with Phase II weight loss drug for $100m
Rhythm to acquire global rights for South Korean LG Chem’s oral obesity drug LB54640 for $100m in cash and equity.
Rhythm to acquire global rights for South Korean LG Chem’s oral obesity drug LB54640 for $100m in cash and equity.
What's Your Reaction?
